Malignant mixed müllerian tumor of the uterus in a patient taking raloxifene

Obstetrics and Gynecology

Volumn 105, Issue 5 II, 2005, Pages 1278-1280

  Goldman, Noah A ^b   De Los Angeles, Maria M ^b   Jones, Joan G ^b   Goldberg, Gary L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IFOSFAMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ABDOMINAL HYSTERECTOMY; ADULT; ANAMNESIS; APPENDECTOMY; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ENDOMETRIUM BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; MIXED MULLERIAN TUMOR; OSTEOPOROSIS; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; TREATMENT OUTCOME; UTERUS BICORNIS; UTERUS HORN; UTERUS TUMOR; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CHEMICALLY INDUCED DISORDER; FOLLOW UP; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEEDLE BIOPSY; OVARIECTOMY; PATHOLOGY; POSTMENOPAUSE OSTEOPOROSIS; UTERUS CANCER;

BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MIXED TUMOR, MULLERIAN; NEOPLASM STAGING; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; RADIOTHERAPY, ADJUVANT; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 20844447333     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000160480.55365.a8     Document Type: Article

References (11)

1. Curtin JP, Kavanagh JJ, Fox H, Spanos WJ Jr. Corpus: mesenchymal tumors. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia (PA): Lippincott-Raven; 1999. p. 962-79.
2. Dunn BK, Ford LG. Breast cancer prevention: results of the National Surgical Adjuvant Breast and Bowel Project (NSABP) breast cancer prevention trial (NSABP P-1: BCPT). Eur J Cancer 2000;36(suppl 4):S49-50.
3. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
4. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000;356:881-7.
5. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cawley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97.
6. Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95-103.
7. Wickerham DL, Fisher B, Wolmark N, Bryant J, Constantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2758-60.
8. Twombly R. FDA issues warning about 'new' tamoxifen risk. J Natl Cancer Inst 2002;94:1122.
9. Altaras MM, Aviram R, Cohen I, Cordoba M, Yarkoni S, Beyth Y. Role of prolonged stimulation of tamoxifen dierapy in the etiology of endometrial sarcomas. Gynecol Oncol 1993;49:255-8.
10. Neven P, Lunde T, Benedetti-Panici P, Tiitinen A, Marinescu B, de Villiers T, et al. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol (E2) and norethisterone acetate. Br J Obstet Gynaecol 2003;110:157-67.
11. Boostanfar R, Amezcua CA, Tourgeman DE, Roy S, Felix JC, Stanczyk FZ. Growth effects of raloxifene, E2, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells. Fertil Steril 2003;79:223-5.